Ms Rachel O'Connell

Senior Research Fellow
NH&MRC Clinical Trials Centre


Map

Biographical details

Dr Rachel O’Connell (PhD, MMedStat, B.Math) is a Senior Research Fellow at the NHMRC Clinical Trials Centre (CTC) University of Sydney. She has 20 years of experience as a biostatistician both in epidemiological research and clinical trials having worked at the CTC since 2001 and prior to that at the Centre for Clinical Epidemiology and Biostatistics, University of Newcastle for 5 years. In November 2011 she attained a PhD in “Forecasting risk in Acute Myocardial Infarction”. She was the consultant statistician for the Sydney Cancer Centre (Royal Prince Alfred Hospital) from 2012-2014 and currently providesstatistical supportat the Kolling Institute, Sydney university,Royal North Shore Hospital.

Teaching and supervision

Masters of Clinical Trials Research: Advanced Trial Design

Selected grants

2014

  • Preventing Adverse Outcomes of Neonatal Encephalopathy with Erythropoietin - the PAEAN Study; Liley H, Hunt R, Jacobs S, Badawi N, Novak I, Askie L, Battin M, O'Connell R; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Does Palliative Chemotherapy Palliate Measuring symptom benefit in recurrent ovarian cancer using patient reported outcomes: The Symptom Benefit Study; Friedlander M, King M, Oza A, Ledermann J, O'Connell R, Sjoquist K, Martyn J, Lee C; National Health and Medical Research Council (NHMRC)/Project Grants.

Selected publications

Download citations: PDF RTF Endnote

Book Chapters

  • O'Connell, R., Gebski, V., Keech, A. (2007). Making sense of trial results: outcomes and estimation. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 99-104). Sydney: AMPCo.

Journals

  • King, M., Stockler, M., O'Connell, R., Buizen, L., Joly, F., Lanceley, A., Hilpert, F., Okamoto, A., Aotani, E., Bryce, J., Costa, D., et al (2018). Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer. Quality of Life Research, 27(1), 59-74. [More Information]
  • Itchins, M., Hayes, S., Gill, A., Cooper, W., O'Connell, R., Howell, V., Clarke, S., Pavlakis, N. (2018). Pattern of care and survival of anaplastic lymphoma kinase rearranged non-small cell lung cancer (ALK+ NSCLC) in an Australian Metropolitan Tertiary Referral Centre: A retrospective cohort analysis. Asia-Pacific Journal of Clinical Oncology, 14(5), e275-e282. [More Information]
  • Roncolato, F., Berton-Rigaud, D., O'Connell, R., Lanceley, A., Sehouli, J., Buizen, L., Okamoto, A., Aotani, E., Lorusso, D., Donnellan, P., Stockler, M., King, M., Friedlander, M., et al (2018). Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) � Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS). Gynecologic Oncology, 148(1), 36-41. [More Information]
  • Ong, K., O'Connell, R., Januszewski, A., Jenkins, A., Xu, A., Sullivan, D., Barter, P., Scott, R., Taskinen, M., Waldman, B., Simes, V., Rye, K., Keech, A., et al (2017). Baseline circulating FGF21 concentrations and increase after fenofibrate treatment predict more rapid glycemic progression in type 2 diabetes: Results from the FIELD study. Clinical Chemistry, 63(7), 1261-1270. [More Information]
  • Deveza, L., Hunter, D., Wajon, A., Bennell, K., Vicenzino, B., Hodges, P., Eyles, J., Jongs, R., Riordan, E., Duong, V., Oo, W., O'Connell, R., Robbins (nee: Ferreira De Meneses), S. (2017). Efficacy of combined conservative therapies on clinical outcomes in patients with thumb base osteoarthritis: Protocol for a randomised, controlled trial (COMBO). BMJ Open, 7(1), 1-10. [More Information]
  • Bonaventura, A., O'Connell, R., Mapagu, C., Beale, P., McNally, O., Mileshkin, L., Grant, P., Hadley, A., Goh, J., Sjoquist, K., Martyn, J., deFazio, A., et al (2017). Paragon (ANZGOG-0903): Phase 2 study of anastrozole in women with estrogen or progesterone receptorypositive platinum-resistant or -refractory recurrent ovarian cancer. International Journal of Gynecological Cancer, 27(5), 900-906. [More Information]
  • Butow, P., Turner, J., Gilchrist, J., Sharpe, L., Smith, A., Fardell, J., Tesson, S., O'Connell, R., Girgis, A., Gebski, V., Asher, R., Bell, M., Beith, J., Grunewald Zola, K., Thewes, B., et al (2017). Randomized Trial of ConquerFear: A Novel, Theoretically Based Psychosocial Intervention for Fear of Cancer Recurrence. Journal of Clinical Oncology, 35(36), 4066-4077. [More Information]
  • Roncolato, F., Joly, F., O'Connell, R., Lanceley, A., Hilpert, F., Buizen, L., Okamoto, A., Aotani, E., Pignata, S., Donnellan, P., Stockler, M., King, M., et al (2017). Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study. The Oncologist, 22(9), 1117-1124. [More Information]
  • Leong, T., Smithers, B., Haustermans, K., Michael, M., Gebski, V., Miller, D., Zalcberg, J., Boussioutas, A., Findlay, M., O'Connell, R., Verghis, J., Simes, R., et al (2017). TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG. Annals of Surgical Oncology, 24(8), 2252-2258. [More Information]
  • Blinman, P., Mileshkin, L., Khaw, P., Goss, G., Johnson, C., Capp, A., Brooks, S., Wain, G., Kolodziej, I., Veillard, A., O'Connell, R., Stockler, M., et al (2016). Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: An ANZGOG substudy of the PORTEC-3 intergroup randomised trial. British Journal of Cancer, 115(10), 1179-1185. [More Information]
  • Ferraro, D., Goldstein, D., O'Connell, R., Zalcberg, J., Sjoquist, K., Tebbutt, N., Grimison, P., McLachlan, S., Lipton, L., Vasey, P., Gebski, V., Aiken, C., et al (2016). TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer. Cancer Chemotherapy and Pharmacology, 78(2), 361-367. [More Information]
  • Neale, R., Armstrong, B., Baxter, C., Duarte Romero, B., Ebeling, P., English, D., Kimlin, M., McLeod, D., O'Connell, R., Van Der Pols, J., et al (2016). The D-Health Trial: A randomized trial of vitamin D for prevention of mortality and cancer. Contemporary Clinical Trials, 48, 83-90. [More Information]
  • Fulcher, J., O'Connell, R., Voysey, M., Emberson, J., Blackwell, L., Mihaylova, B., Simes, J., Collins, R., Kirby, A., Colhoun, H., Keech, A., et al (2015). Efficacy and safety of LDL-lowering therapy among men and women: Meta-analysis of individual data from 174 000 participants in 27 randomised trials. The Lancet, 385(9976), 1397-1405. [More Information]
  • Gupta, R., O'Connell, R., Haynes, A., Stricker, P., Barrett, W., Turner, J., Delprado, W., Horvath, L., Kench, J. (2015). Extraprostatic Extension (EPE) of Prostatic Carcinoma: Is its Proximity to Surgical margin or Gleason Score Important? BJU International, 116(3), 343-350. [More Information]
  • Ong, K., Januszewski, A., O'Connell, R., Buizen, L., Jenkins, A., Xu, A., Sullivan, D., Barter, P., Scott, R., Taskinen, M., Rye, K., Keech, A. (2015). Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study. Diabetologia, 59(8), 2035-2044. [More Information]
  • Ong, K., Januszewski, A., O'Connell, R., Jenkins, A., Xu, A., Sullivan, D., Barter, P., Hung, W., Scott, R., Taskinen, M., Keech, A., Rye, K. (2015). The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study. Diabetologia, 58(3), 464-473. [More Information]
  • Carter, J., Philp, S., O'Connell, R. (2014). A 5-Year Review of Gynaecological Oncology Patients Managed by a Fast Track Surgery Program. International Journal of Clinical Medicine, 5(1), 36-41. [More Information]
  • Moloney, F., Guitera, P., Coates, E., Haass, N., Ho, K., Khoury, R., O'Connell, R., Raudonikis, L., Schmid, H., Mann, G., Menzies, S. (2014). Detection of Primary Melanoma in Individuals at Extreme High Risk: A Prospective 5-year Follow-up Study. JAMA Dermatology, 150(8), 819-827. [More Information]
  • King, M., Stockler, M., Butow, P., O'Connell, R., Voysey, M., Oza, A., Gillies, K., Donovan, H., Mercieca-Bebber, R., Martyn, J., Sjoquist, K., Friedlander, M. (2014). Development of the Measure of Ovarian Symptoms and Treatment Concerns: Aiming for Optimal Measurement of Patient-Reported Symptom Benefit with Chemotherapy for Symptomatic Ovarian Cancer. International Journal of Gynecological Cancer, 24(5), 865-873. [More Information]
  • Waldman, B., Jenkins, A., Davis, T., Taskinen, M., Scott, R., O'Connell, R., Gebski, V., Ng, M., Keech, A. (2014). HDL-C and HDL-C/ApoA-I Predict Long-Term Progression of Glycemia in Established Type 2 Diabetes. Diabetes Care, 37(8), 2351-2358. [More Information]
  • Friedlander, M., Stockler, M., O'Connell, R., Voysey, M., Oza, A., Gillies, K., Donovan, H., Martyn, J., Sjoquist, K., Butow, P., King, M., et al (2014). Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer: a reality check: results of stage 1 of the gynecologic cancer intergroup symptom benefit study. International Journal of Gynecological Cancer, 24(5), 857-864. [More Information]
  • Sjoquist, K., Friedlander, M., O'Connell, R., Voysey, M., King, M., Stockler, M., Oza, A., Gillies, K., Martyn, J., Butow, P. (2013). Hope, Quality of Life, and Benefit From Treatment in Women Having Chemotherapy for Platinum-Resistant/Refractory Recurrent Ovarian Cancer: The Gynecological Cancer Intergroup Symptom Benefit Study. The Oncologist, 18(11), 1221-1228. [More Information]
  • Chan, K., O'Connell, R., Sullivan, D., Hoffmann, L., Rajamani, K., Whiting, M., Donoghoe, M., Vanhala, M., Hamer, A., Yu, B., Stocker, R., Ng, M., Keech, A. (2013). Plasma total bilirubin levels predict amputation events in type 2 diabetes mellitus: the fenofibrate intervention and event lowering in diabetes (field) study. Diabetologia, 56(4), 724-736. [More Information]
  • Hankey, G., Anderson, N., Ting, R., Veillard, A., Romo, M., Wosik, M., Sullivan, D., O'Connell, R., Hunt, D., Keech, A. (2013). Rates and predictors of risk of stroke and its subtypes in diabetes: A prospective observational study. Journal of Neurology, Neurosurgery and Psychiatry, 84(3), 281-287. [More Information]
  • Ong, K., Rye, K., O'Connell, R., Jenkins, A., Brown, C., Xu, A., Sullivan, D., Barter, P., Keech, A. (2012). Long-Term Fenofibrate Therapy Increases Fibroblast Growth Factor 21 and Retinol-Binding Protein 4 in Subjects with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 97(12), 4701-4708. [More Information]
  • Marschner, I., Gillet, A., O'Connell, R. (2012). Stratified additive Poisson models: Computational methods and applications in clinical epidemiology. Computational Statistics and Data Analysis, 56(5), 1115-1130. [More Information]
  • Ng, M., Yong, A., Ho, M., Shah, M., Chawantanpipat, C., O'Connell, R., Keech, A., Kritharides, L., Fearon, W. (2012). The Index of Microcirculatory Resistance Predicts Myocardial Infarction Related to Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 5(4), 515-522. [More Information]
  • Davis, T., Ting, R., Best, J., Donoghoe, M., Drury, P., Sullivan, D., Jenkins, A., O'Connell, R., Whiting, M., Glasziou, P., Simes, R., Gebski, V., Keech, A., et al (2011). Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia, 54(2), 280-290. [More Information]
  • Cox, K., Goel, S., O'Connell, R., Boyer, M., Beale, P., Simes, R., Stockler, M. (2011). Randomized cross-over trial comparing inpatient and outpatient administration of high-dose cisplatin. Internal Medicine Journal, 41(2), 172-178. [More Information]
  • Simes, R., Voysey, M., O'Connell, R., Glasziou, P., Best, J., Scott, R., Pardy, C., Byth Wilson, K., Sullivan, D., Ehnholm, C., Keech, A. (2010). A novel method to adjust efficacy estimates for uptake of other active treatments in long-term clinical trials. PloS One, 5(1), e8580-1-e8580-10. [More Information]
  • Davis, T., Ting, R., Best, J., Donoghoe, M., Drury, P., Sullivan, D., Jenkins, A., O'Connell, R., Whiting, M., Glasziou, P., Simes, R., Gebski, V., Keech, A., et al (2010). Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia, 54(2), 280-290. [More Information]
  • Simes, R., O'Connell, R., Aylward, P., Varshavsky, S., Diaz, R., Wilcox, R., Armstrong, P., Granger, C., French, J., Van de Werf, F., Marschner, I., et al (2010). Unexplained international differences in clinical outcomes after acute myocardial infarction and fibrinolytic therapy: Lessons from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial. American Heart Journal, 159(6), 988-997. [More Information]
  • O'Connell, R., Hudson, M. (2009). Risk of mortality after acute myocardial infarction: Performance of model updating methods for application in different geographical regions. Computational Statistics and Data Analysis, 53(3), 834-846. [More Information]
  • Keech, A., Mitchell, P., Summanen, P., O'Day, J., Davis, T., Moffitt, M., Taskinen, M., Simes, R., Tse, D., Williamson, E., Merrifield, A., O'Connell, R., et al (2007). Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. The Lancet, 370(9600), 1687-1697. [More Information]
  • Stockler, M., O'Connell, R., Nowak, A., Goldstein, D., Turner, J., Wilcken, N., Wyld, D., Abdi, E., Glasgow, A., Beale, P., Dhillon, H., Heritier, S., Carter, C., Hickie, I., Simes, R., et al (2007). Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. The Lancet Oncology, 8(7), 603-612. [More Information]
  • Edmond, J., French, J., Aylward, P., Wong, C., Stewart, R., Williams, B., de Pasquale, C., O'Connell, R., van den Berg, K., Van de Werf, F., Simes, R., et al (2007). Variations in the use of emergency PCI for the treatment of re-infarction following intravenous fibrinolytic therapy: impact on outcomes in HERO-2. European Heart Journal, 28(12), 1418-1424. [More Information]
  • Edmond, J., French, J., Stewart, R., Aylward, P., de Pasquale, C., Williams, B., O'Connell, R., Simes, R., White, H. (2006). Frequency of recurrent ST-elevation myocardial infarction after fibrinolytic therapy in a different territory as a manifestation of multiple unstable coronary arterial plaques. American Journal of Cardiology, 97(7), 947-951. [More Information]
  • O'Connell, R., Edmond, J., French, J., Aylward, P., Simes, R., White, H. (2005). A simple prognostic score for the re-infarction risk following fibrinolytic therapy for myocardial infarction - data from HERO-2. European Heart Journal, 26(Suppl 1), 561-561.
  • Cox, K., O'Connell, R., Stockler, M., Boyer, M., Beale, P., Simes, R. (2004). A randomized crossover trial of giving high-dose cisplatin with or without an overnight stay in hospital: Patients' preferences, quality of life, safety and resource use. Journal of Clinical Oncology, 22(14S), 547S-547S.
  • O'Connell, R., Gebski, V., Keech, A. (2004). Making Sense Of Trial Results: Outcomes And Estimation. Medical Journal of Australia, 180(3), 128-130.

2018

  • King, M., Stockler, M., O'Connell, R., Buizen, L., Joly, F., Lanceley, A., Hilpert, F., Okamoto, A., Aotani, E., Bryce, J., Costa, D., et al (2018). Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer. Quality of Life Research, 27(1), 59-74. [More Information]
  • Itchins, M., Hayes, S., Gill, A., Cooper, W., O'Connell, R., Howell, V., Clarke, S., Pavlakis, N. (2018). Pattern of care and survival of anaplastic lymphoma kinase rearranged non-small cell lung cancer (ALK+ NSCLC) in an Australian Metropolitan Tertiary Referral Centre: A retrospective cohort analysis. Asia-Pacific Journal of Clinical Oncology, 14(5), e275-e282. [More Information]
  • Roncolato, F., Berton-Rigaud, D., O'Connell, R., Lanceley, A., Sehouli, J., Buizen, L., Okamoto, A., Aotani, E., Lorusso, D., Donnellan, P., Stockler, M., King, M., Friedlander, M., et al (2018). Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) � Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS). Gynecologic Oncology, 148(1), 36-41. [More Information]

2017

  • Ong, K., O'Connell, R., Januszewski, A., Jenkins, A., Xu, A., Sullivan, D., Barter, P., Scott, R., Taskinen, M., Waldman, B., Simes, V., Rye, K., Keech, A., et al (2017). Baseline circulating FGF21 concentrations and increase after fenofibrate treatment predict more rapid glycemic progression in type 2 diabetes: Results from the FIELD study. Clinical Chemistry, 63(7), 1261-1270. [More Information]
  • Deveza, L., Hunter, D., Wajon, A., Bennell, K., Vicenzino, B., Hodges, P., Eyles, J., Jongs, R., Riordan, E., Duong, V., Oo, W., O'Connell, R., Robbins (nee: Ferreira De Meneses), S. (2017). Efficacy of combined conservative therapies on clinical outcomes in patients with thumb base osteoarthritis: Protocol for a randomised, controlled trial (COMBO). BMJ Open, 7(1), 1-10. [More Information]
  • Bonaventura, A., O'Connell, R., Mapagu, C., Beale, P., McNally, O., Mileshkin, L., Grant, P., Hadley, A., Goh, J., Sjoquist, K., Martyn, J., deFazio, A., et al (2017). Paragon (ANZGOG-0903): Phase 2 study of anastrozole in women with estrogen or progesterone receptorypositive platinum-resistant or -refractory recurrent ovarian cancer. International Journal of Gynecological Cancer, 27(5), 900-906. [More Information]
  • Butow, P., Turner, J., Gilchrist, J., Sharpe, L., Smith, A., Fardell, J., Tesson, S., O'Connell, R., Girgis, A., Gebski, V., Asher, R., Bell, M., Beith, J., Grunewald Zola, K., Thewes, B., et al (2017). Randomized Trial of ConquerFear: A Novel, Theoretically Based Psychosocial Intervention for Fear of Cancer Recurrence. Journal of Clinical Oncology, 35(36), 4066-4077. [More Information]
  • Roncolato, F., Joly, F., O'Connell, R., Lanceley, A., Hilpert, F., Buizen, L., Okamoto, A., Aotani, E., Pignata, S., Donnellan, P., Stockler, M., King, M., et al (2017). Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study. The Oncologist, 22(9), 1117-1124. [More Information]
  • Leong, T., Smithers, B., Haustermans, K., Michael, M., Gebski, V., Miller, D., Zalcberg, J., Boussioutas, A., Findlay, M., O'Connell, R., Verghis, J., Simes, R., et al (2017). TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG. Annals of Surgical Oncology, 24(8), 2252-2258. [More Information]

2016

  • Blinman, P., Mileshkin, L., Khaw, P., Goss, G., Johnson, C., Capp, A., Brooks, S., Wain, G., Kolodziej, I., Veillard, A., O'Connell, R., Stockler, M., et al (2016). Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: An ANZGOG substudy of the PORTEC-3 intergroup randomised trial. British Journal of Cancer, 115(10), 1179-1185. [More Information]
  • Ferraro, D., Goldstein, D., O'Connell, R., Zalcberg, J., Sjoquist, K., Tebbutt, N., Grimison, P., McLachlan, S., Lipton, L., Vasey, P., Gebski, V., Aiken, C., et al (2016). TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer. Cancer Chemotherapy and Pharmacology, 78(2), 361-367. [More Information]
  • Neale, R., Armstrong, B., Baxter, C., Duarte Romero, B., Ebeling, P., English, D., Kimlin, M., McLeod, D., O'Connell, R., Van Der Pols, J., et al (2016). The D-Health Trial: A randomized trial of vitamin D for prevention of mortality and cancer. Contemporary Clinical Trials, 48, 83-90. [More Information]

2015

  • Fulcher, J., O'Connell, R., Voysey, M., Emberson, J., Blackwell, L., Mihaylova, B., Simes, J., Collins, R., Kirby, A., Colhoun, H., Keech, A., et al (2015). Efficacy and safety of LDL-lowering therapy among men and women: Meta-analysis of individual data from 174 000 participants in 27 randomised trials. The Lancet, 385(9976), 1397-1405. [More Information]
  • Gupta, R., O'Connell, R., Haynes, A., Stricker, P., Barrett, W., Turner, J., Delprado, W., Horvath, L., Kench, J. (2015). Extraprostatic Extension (EPE) of Prostatic Carcinoma: Is its Proximity to Surgical margin or Gleason Score Important? BJU International, 116(3), 343-350. [More Information]
  • Ong, K., Januszewski, A., O'Connell, R., Buizen, L., Jenkins, A., Xu, A., Sullivan, D., Barter, P., Scott, R., Taskinen, M., Rye, K., Keech, A. (2015). Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study. Diabetologia, 59(8), 2035-2044. [More Information]
  • Ong, K., Januszewski, A., O'Connell, R., Jenkins, A., Xu, A., Sullivan, D., Barter, P., Hung, W., Scott, R., Taskinen, M., Keech, A., Rye, K. (2015). The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study. Diabetologia, 58(3), 464-473. [More Information]

2014

  • Carter, J., Philp, S., O'Connell, R. (2014). A 5-Year Review of Gynaecological Oncology Patients Managed by a Fast Track Surgery Program. International Journal of Clinical Medicine, 5(1), 36-41. [More Information]
  • Moloney, F., Guitera, P., Coates, E., Haass, N., Ho, K., Khoury, R., O'Connell, R., Raudonikis, L., Schmid, H., Mann, G., Menzies, S. (2014). Detection of Primary Melanoma in Individuals at Extreme High Risk: A Prospective 5-year Follow-up Study. JAMA Dermatology, 150(8), 819-827. [More Information]
  • King, M., Stockler, M., Butow, P., O'Connell, R., Voysey, M., Oza, A., Gillies, K., Donovan, H., Mercieca-Bebber, R., Martyn, J., Sjoquist, K., Friedlander, M. (2014). Development of the Measure of Ovarian Symptoms and Treatment Concerns: Aiming for Optimal Measurement of Patient-Reported Symptom Benefit with Chemotherapy for Symptomatic Ovarian Cancer. International Journal of Gynecological Cancer, 24(5), 865-873. [More Information]
  • Waldman, B., Jenkins, A., Davis, T., Taskinen, M., Scott, R., O'Connell, R., Gebski, V., Ng, M., Keech, A. (2014). HDL-C and HDL-C/ApoA-I Predict Long-Term Progression of Glycemia in Established Type 2 Diabetes. Diabetes Care, 37(8), 2351-2358. [More Information]
  • Friedlander, M., Stockler, M., O'Connell, R., Voysey, M., Oza, A., Gillies, K., Donovan, H., Martyn, J., Sjoquist, K., Butow, P., King, M., et al (2014). Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer: a reality check: results of stage 1 of the gynecologic cancer intergroup symptom benefit study. International Journal of Gynecological Cancer, 24(5), 857-864. [More Information]

2013

  • Sjoquist, K., Friedlander, M., O'Connell, R., Voysey, M., King, M., Stockler, M., Oza, A., Gillies, K., Martyn, J., Butow, P. (2013). Hope, Quality of Life, and Benefit From Treatment in Women Having Chemotherapy for Platinum-Resistant/Refractory Recurrent Ovarian Cancer: The Gynecological Cancer Intergroup Symptom Benefit Study. The Oncologist, 18(11), 1221-1228. [More Information]
  • Chan, K., O'Connell, R., Sullivan, D., Hoffmann, L., Rajamani, K., Whiting, M., Donoghoe, M., Vanhala, M., Hamer, A., Yu, B., Stocker, R., Ng, M., Keech, A. (2013). Plasma total bilirubin levels predict amputation events in type 2 diabetes mellitus: the fenofibrate intervention and event lowering in diabetes (field) study. Diabetologia, 56(4), 724-736. [More Information]
  • Hankey, G., Anderson, N., Ting, R., Veillard, A., Romo, M., Wosik, M., Sullivan, D., O'Connell, R., Hunt, D., Keech, A. (2013). Rates and predictors of risk of stroke and its subtypes in diabetes: A prospective observational study. Journal of Neurology, Neurosurgery and Psychiatry, 84(3), 281-287. [More Information]

2012

  • Ong, K., Rye, K., O'Connell, R., Jenkins, A., Brown, C., Xu, A., Sullivan, D., Barter, P., Keech, A. (2012). Long-Term Fenofibrate Therapy Increases Fibroblast Growth Factor 21 and Retinol-Binding Protein 4 in Subjects with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 97(12), 4701-4708. [More Information]
  • Marschner, I., Gillet, A., O'Connell, R. (2012). Stratified additive Poisson models: Computational methods and applications in clinical epidemiology. Computational Statistics and Data Analysis, 56(5), 1115-1130. [More Information]
  • Ng, M., Yong, A., Ho, M., Shah, M., Chawantanpipat, C., O'Connell, R., Keech, A., Kritharides, L., Fearon, W. (2012). The Index of Microcirculatory Resistance Predicts Myocardial Infarction Related to Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 5(4), 515-522. [More Information]

2011

  • Davis, T., Ting, R., Best, J., Donoghoe, M., Drury, P., Sullivan, D., Jenkins, A., O'Connell, R., Whiting, M., Glasziou, P., Simes, R., Gebski, V., Keech, A., et al (2011). Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia, 54(2), 280-290. [More Information]
  • Cox, K., Goel, S., O'Connell, R., Boyer, M., Beale, P., Simes, R., Stockler, M. (2011). Randomized cross-over trial comparing inpatient and outpatient administration of high-dose cisplatin. Internal Medicine Journal, 41(2), 172-178. [More Information]

2010

  • Simes, R., Voysey, M., O'Connell, R., Glasziou, P., Best, J., Scott, R., Pardy, C., Byth Wilson, K., Sullivan, D., Ehnholm, C., Keech, A. (2010). A novel method to adjust efficacy estimates for uptake of other active treatments in long-term clinical trials. PloS One, 5(1), e8580-1-e8580-10. [More Information]
  • Davis, T., Ting, R., Best, J., Donoghoe, M., Drury, P., Sullivan, D., Jenkins, A., O'Connell, R., Whiting, M., Glasziou, P., Simes, R., Gebski, V., Keech, A., et al (2010). Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia, 54(2), 280-290. [More Information]
  • Simes, R., O'Connell, R., Aylward, P., Varshavsky, S., Diaz, R., Wilcox, R., Armstrong, P., Granger, C., French, J., Van de Werf, F., Marschner, I., et al (2010). Unexplained international differences in clinical outcomes after acute myocardial infarction and fibrinolytic therapy: Lessons from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial. American Heart Journal, 159(6), 988-997. [More Information]

2009

  • O'Connell, R., Hudson, M. (2009). Risk of mortality after acute myocardial infarction: Performance of model updating methods for application in different geographical regions. Computational Statistics and Data Analysis, 53(3), 834-846. [More Information]

2007

  • Keech, A., Mitchell, P., Summanen, P., O'Day, J., Davis, T., Moffitt, M., Taskinen, M., Simes, R., Tse, D., Williamson, E., Merrifield, A., O'Connell, R., et al (2007). Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. The Lancet, 370(9600), 1687-1697. [More Information]
  • Stockler, M., O'Connell, R., Nowak, A., Goldstein, D., Turner, J., Wilcken, N., Wyld, D., Abdi, E., Glasgow, A., Beale, P., Dhillon, H., Heritier, S., Carter, C., Hickie, I., Simes, R., et al (2007). Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. The Lancet Oncology, 8(7), 603-612. [More Information]
  • O'Connell, R., Gebski, V., Keech, A. (2007). Making sense of trial results: outcomes and estimation. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 99-104). Sydney: AMPCo.
  • Edmond, J., French, J., Aylward, P., Wong, C., Stewart, R., Williams, B., de Pasquale, C., O'Connell, R., van den Berg, K., Van de Werf, F., Simes, R., et al (2007). Variations in the use of emergency PCI for the treatment of re-infarction following intravenous fibrinolytic therapy: impact on outcomes in HERO-2. European Heart Journal, 28(12), 1418-1424. [More Information]

2006

  • Edmond, J., French, J., Stewart, R., Aylward, P., de Pasquale, C., Williams, B., O'Connell, R., Simes, R., White, H. (2006). Frequency of recurrent ST-elevation myocardial infarction after fibrinolytic therapy in a different territory as a manifestation of multiple unstable coronary arterial plaques. American Journal of Cardiology, 97(7), 947-951. [More Information]

2005

  • O'Connell, R., Edmond, J., French, J., Aylward, P., Simes, R., White, H. (2005). A simple prognostic score for the re-infarction risk following fibrinolytic therapy for myocardial infarction - data from HERO-2. European Heart Journal, 26(Suppl 1), 561-561.

2004

  • Cox, K., O'Connell, R., Stockler, M., Boyer, M., Beale, P., Simes, R. (2004). A randomized crossover trial of giving high-dose cisplatin with or without an overnight stay in hospital: Patients' preferences, quality of life, safety and resource use. Journal of Clinical Oncology, 22(14S), 547S-547S.
  • O'Connell, R., Gebski, V., Keech, A. (2004). Making Sense Of Trial Results: Outcomes And Estimation. Medical Journal of Australia, 180(3), 128-130.

To update your profile click here. For support on your academic profile contact .